Role of platelet activating factor in pathogenesis of acute respiratory distress syndrome

Chinese Medical Journal

Volumn 120, Issue 20, 2007, Pages 1840-1844

  Xu, Wei ^a   Xia, Shi Hai ^a   Wang, Huo ^a   Chen, Hong ^a   Wang, Yu Liang ^a  

^a Medical College   (China)

Author keywords

Acute respiratory distress syndrome; Platelet activating factor

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; APAFANT; BEPAFANT; INTERLEUKIN 1; MODIPAFANT; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BLOOD VESSEL PERMEABILITY; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; LUNG EDEMA; LUNG VASCULAR RESISTANCE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PULMONARY HYPERTENSION;

EID: 36148985679     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200710020-00022     Document Type: Article

References (59)

1. Lewandowski K, Lewandowski M. Epidemiology of ARDS. Minerva Anestesiol 2006; 72: 473-477.
2. Zhou W, McCollum MO, Levine BA, Olson MS. Role of platelet-activating factor in pancreatitis-associated acute lung injury in the rat. Am J Pathol 1992; 140: 971-979.
3. Tu W, Li J, Zhu W. Influences of BN50739 on neutrophil elastase and phospholipase A2 in lung and tracheal mucosa of pigs with acute severe pancreatitis. Chin J Tuberc Respir (Chin) 2000; 23: 595-598.
4. Huang̊ YC, Kennedy TP, Su YF, Watkins WD, Whorton AR, Piantadosi CA. Protection against platelet-activating factor-induced injury by interferon inducer in perfused rabbit lung. J Appl Physiol 1993; 74: 251-258.
5. Inui K. Participation of platelet activating factor in the pulmonary injury during cardiopulmonary bypass. Nippon Kyobu Geka Gakkai Zasshi 1993; 41: 238-246.
6. Matsumoto K, Taki F, Kondo Y, Taniguchi H, Takagi K, Matsuzaki M, et al. Platelet activating factor and tumor necrosis factor-α in bronchoalveolar lavage fluid of patients with ARDS. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31: 330-335.
7. Karagiorga G, Nakos G, Galiatsou E, Lekka ME. Biochemical parameters of bronchoalveolar lavage fluid in fat embolism. Intensive Care Med 2006; 32: 116-123.
8. Nagase T, Ishii S, Kume K, Uozumi N, Izumi T, Ouchi Y, et al. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J Clin Invest 1999; 104: 1071-1076.
9. Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993; 292: 617-629.
10. Summers JB, Albert DH. Platelet activating factor antagonists. Adv Pharmacol 1995; 32: 67-168.
11. Arai H. Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat 2002; 68-69: 83-94.
12. Chung KF. Platelet-activating factor in inflammation and pulmonary disorders. Clin Sci 1992; 83: 127-138.
13. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000; 69: 419-445.
14. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM, The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30- 294S-301S.
15. Cui S, Shibamoto T, Liu W, Takano H, Kurata Y. Effects of platelet-activating factor, thromboxane A2 and leukotriene D4 on isolated perfused rat liver. Prostaglandins Other Lipid Mediat 2006; 80: 35-45.
16. Kushikata T, Fang J, Krueger JM. Platelet activating factor and its metabolite promote sleep in rabbits. Neurosci Lett 2006; 394: 233-238.
17. Tran KC, Ryu JY, McLarnon JG. Induction of angiogenesis by platelet-activating factor in the rat striatum. Neuroreport 2005; 16: 1579-1583.
18. Murakami K, Okajima K, Uchiba M, Johno M, Okabe H, Takatsuki K. A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. Thromb Haemost 1996; 75: 965-970.
19. Lee YM, Hybertson BM, Cho HG, Terada LS, Cho O, Repine AJ, et al. Platelet-activating factor contributes to acute lung leak in rats given interleukin-1 intratracheally. Am J Physiol Lung Cell Mol Physiol 2000; 279: L75-L80.
20. Miotla JM, Jeffery PK, Hellewell PG. Platelet-activating factor plays a pivotal role in the induction of experimental lung injury. Am J Respir Cell Mol Biol 1998; 18: 197-204.
21. Weiland JE, Davis WB, Holter JF, Mohammed JR, Dirinsky PM, Gadek JE. Lung neutrophils in the adult respiratory distress syndrome. Clinical and pathophysiologic significance. Am Rev Respir Dis 1986; 133: 218-225.
22. Perkins GD, Nathani N, McAuley DF, Gao F, Thickett DR. In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax 2007; 62: 36-42.
23. Heflin AC, Brigham KL. Prevention by granulocyte depletion of increased lung vascular permeability of sheep following endotoxaemia. J Clin Invest 1981; 68: 1253-1260.
24. Bhatia M, Saluja AK, Hofbauer B, Lee HS, Frossard JL, Steer ML. The effects of neutrophil depletion on a completely noninvasive model of acute pancreatitis-associated lung injury. Int J Pancreatol 1998; 24:77-83.
25. Biffl WL, Moore EE, Moore FA, Carl VS, Kim FJ, Franciose RJ. Interleukin-6 potentiates neutrophil priming with platelet-activating factor. Arch Surg 1994; 129: 1131-1136.
26. Issekatz AC, Ripley M. The effect of intravascular neutrophil chemotactic factors on blood neutrophil and platelet kinetics. Am J Hematol 1986; 21: 157-171.
27. Lee YM, Hybertson BM, Cho HG, Repine JE. Platelet-activating factor induces lung inflammation and leak in rats: hydrogen peroxide production along neutrophil-lung endothelial cell interfaces. J Lab Clin Med 2002; 140: 312-319.
28. Rabinovici R, Esser KM, Lysko PG, Yue TL, Griswold DE, Hillegass LM, et al. Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ Res 1991; 69: 12-25.
29. Schaefer MB, Ott J, Mohr A, Bi MH, Grosz A, Weissmann N, et al. Immunomodulation by n-3- versus n-6-rich lipid emulsions in murine acute lung injury - role of platelet-activating factor receptor. Crit Care Med 2007; 35: 544-554.
30. Matsumoto K, Taki F, Kondoh Y, Taniguchi H, Takagi K. Platelet-activating factor bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Clin Exp Pharmacol Physiol 1992; 19: 509-515.
31. Chang SW, Ohara N, Kuo G, Voelkel NF. Tumor necrosis factor-induced lung injury is not mediated by platelet-activating factor. Am J Physiol 1989; 257: L232-L239.
32. Bulger EM, Arbabi S, Garcia I, Maier RV. The macrophage response to endotoxin requires platelet activating factor. Shock 2002; 17: 173-179.
33. Armstrong L, Millar AB. Relative production of tumour necrosis factor α and interleukin 10 in adult respiratory distrtss syndrome. Thorax 1997; 52: 442-446.
34. Pugin J, Ricou B, Steinberg KP, Suter PM, Martin TR. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am J Respir Crit Care Med 1996; 153: 1850-1856.
35. Olson NC, Joyce PB, Fleisher LN. Monohydroxyeicosatetraenoic acids during porcine endotoxemia. Effect of a platelet-activating factor receptor antagonist. Lab Invest 1990; 63: 221-232.
36. Rabinovici R, Sofronski MD, Renz JF, Hillegas LM, Esser KM,, Vernick J, et al. Platelet activating factor mediates interleukin-2-induced lung injury in the rat. J Clin Invest 1992; 89: 1669-1673.
37. Voelkel NF, Czartolomna J, Simpson J, Murphy RC. FMLP causes eicosanoid-dependent vasoconstriction and edema in lungs from endotoxin-primed rats. Am Rev Respir Dis 1992; 145: 701-711.
38. Goggel R, Hoffman S, Nusing R, Narumiya S, Uhlig S. Platelet-activating factor-induced pulmonary edema is partly mediated by prostaglandin E2, E-prostanoid 3-receptors, and potassium channels. Am J Respir Crit Care Med 2002; 166: 657-662.
39. Uhlig S, Wollin L, Wendel A. Contributions of thromboxane and leukotrienes to platelet-activating factor induced impairment of lung function in the rat. J Appl Physiol 1994; 77: 262-269.
40. Akagi M, Nishioka E, Kanoh R, Tachibana M, Fukuishi N. Inhibitor effects of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats. Drug Res 1997; 47: 1364-1369.
41. Uhlig S, Goggel R, Engel S. Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung. Pharmacol Rep 2005; 57 Suppl: 206-221.
42. Matsuda N, Hattori Y, Jesmin S, Gando S. Nuclear factor-κB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 2005; 67: 1018-1025.
43. Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Annu Rev Med 2001; 52: 221-237.
44. Tasaka S, Hasegawa N, Ishizaka A. Pharmacology of acute lung injury. Pulm Pharmacol Ther 2002; 15: 83-95.
45. Mojarad M, Hamasaki Y, Said SI. Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. A preliminary report. Bull Eur Physiopathol Respir 1983; 19: 125-256.
46. Goggel R, Uhlig S. The inositol trisphosphate pathway mediates platelet-activating-factor-induced pulmonary oedema. Eur Respir J 2005; 25: 849-857.
47. Salzer WL, McCall CE. Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury. J Clin Invest 1990; 85: 1135-1143.
48. Rabinovici R, Bugelski PJ, Esser KM, Hillegass LM, Vernick J, Feuerstein G. ARDS-like lung injury produced by endotoxin in platelet-activating factor-primed rats. J Appl Physiol 1993; 74: 1791-1802.
49. Byrne K, Sessler CN, Carey PD, Sielaff TD, Vasquez A, Tatum JL, et al. Platelet-activating factor in porcine Pseudomonas acute lung injury. J Surg Res 1991; 50:111-118.
50. Galloway SW, Kingsnorth AN. Lung injury in the microembolic model of acute pancreatitis and amelioration by lexipafant (BB-882), a platelet-activating factor antagonist. Pancreas 1996; 13:140-146.
51. Goggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, et al. PAF-mediated pulmonary-edema: a new role for acid sphingomyelinase and ceramide. Nat Med 2004; 10: 155-160.
52. Yu P, Hatakeyama T, Aramoto H, Miyata T, Shigematsu H, Nagaya H, et al. Mitogen-activated protein kinases regulate platelet-activating factor-induced hyperpermeability. Microcirculation 2005; 12: 637-643.
53. Beiderlinden M, Kuehl H, Boes T, Peters J. Prevalence of pulmonary hypertension associated with severe acute respiratory distress syndrome: predictive value of computed tomography. Intensive Care Med 2006; 32:852-857.
54. Sloane PJ, Gee MH, Gottlieb JE, Albertine KH, Peters SP, Burns JR, et al. A multicenter registry of patients with acute respiratory distress syndrome. Am Rev Respir Dis 1992; 146: 419-426.
55. Gillespie MN, Bowdy BD. Impact of platelet activating factor on vascular responsiveness in isolated rat lungs. J Pharmacol Exp Ther 1986; 236: 396-402.
56. McCormack DG, Crawley DE, Barnes PJ, Evans TW. Bleomycin-induced lung injury in rats selectively abolishes hypoxic pulmonary vasoconstriction: evidence against a role for platelet-activating factor. Clin Sci (Lond) 1992; 82: 259-264.
57. Witzenrath M, Gutbier B, Owen JS, Schmeck B, Mitchell TJ, Mayer K, et al. Role of platelet-activating factor in pneumolysin-induced acute lung injury. Crit Care Med 2007; 35: 1756-1762.
58. Clavijo LC, Carter MB, Matheson PJ, Wills-Frank LA, Wilson MA, Wead WB, et al. Platelet-activating factor and bacteremia-induced pulmonary hypertension. J Surg Res 2000; 88:173-180.
59. Khoury J, Langleben D. Platelet-activating factor stimulates lung pericyte growth in vitro. Am J Physiol 1996; 270: L298-L304.